HedgeChatter

  • Home /
  • Tag Archives

ABBV

[$$] Gilead a Given for Hepatitis C Favorite

moreView todays social media effects on ABBVView the latest stocks trending across Twitter. Click to view dashboardSee who AbbVie is hiring next, click here to view […]

February 11, 2014 Bystocknews , Comments Off on [$$] Gilead a Given for Hepatitis C Favorite read more

Enanta’s Abbvie Partnership Is Going Places But It’s Still Overvalued

[at Seeking Alpha] – There’s plenty to be excited about regarding the recently listed Enanta Pharmaceuticals ( ENTA ). Its lead compound, ABT-450, is a component of Abbvie’s ( ABBV ) promising hepatitis C virus (HCV) combination … moreView todays social media effects on ABBVView the latest stocks trending across Twitter. Click to view dashboard […]

December 16, 2013 Bystocknews , Comments Off on Enanta’s Abbvie Partnership Is Going Places But It’s Still Overvalued read more

AbbVie Reports Encouraging Data on HCV Drug

[Zacks] – AbbVie released positive results from a phase III study evaluating 3D regimen. moreView todays social media effects on ABBVView the latest stocks trending across Twitter. Click to view dashboard […]

December 11, 2013 Bystocknews , Comments Off on AbbVie Reports Encouraging Data on HCV Drug read more

A 2013 Top Ten Wall Street Transcript Interview with David Ferreiro, Executive Director and Senior Analyst at Oppenheimer & Co., Covering the Biotechnology Sector: Opportunities in Hepatitis C and Genomic Technologies

[Wall Street Transcript] – 67 WALL STREET, New York – December 9, 2013 – The Wall Street Transcript has just published its Top Ten Equity Analyst Interviews of 2013 Report. This special feature contains expert industry commentary … moreView todays social media effects on ABBVView the latest stocks trending across Twitter. Click to view dashboard […]

December 9, 2013 Bystocknews , Comments Off on A 2013 Top Ten Wall Street Transcript Interview with David Ferreiro, Executive Director and Senior Analyst at Oppenheimer & Co., Covering the Biotechnology Sector: Opportunities in Hepatitis C and Genomic Technologies read more

AbbVie leukemia drug impresses in early-stage trial

[Reuters] – An experimental AbbVie Inc drug for leukemia controlled or eliminated signs of the disease in more than 80 percent of patients who had failed to benefit from previous treatments, an unprecedented finding that could spur use of the medicine fo moreView todays social media effects on ABBVView the latest stocks trending across Twitter. Click to view dashboard […]

December 8, 2013 Bystocknews , Comments Off on AbbVie leukemia drug impresses in early-stage trial read more